论文部分内容阅读
自1964年lPrichard等报告普萘洛尔(心得安propranoloum)治疗高血压以来,β阻断剂已广泛用于临床,因为β阻断剂降压作用缓和,又有抗心绞痛和抗心律失常作用,对合并有缺血性心脏病、过速性心律失常的高血压病患者尤为适用,而对儿茶酚胺及血浆肾素活性高的年轻人高血压及与情绪波动有关的高血压病人可作为首选。可是,一般的β阻断剂如普萘洛尔等应用除常常引起心动过缓外,还有诱发心衰、影响血脂、糖代谢等副作用,在一定程度上限制其应用。
Since 1964, lPrichard et al reported propranolol (propranolol propranolol) treatment of hypertension since the beta blockers have been widely used in clinical, because beta blockers relief of antihypertensive effect, there are anti-angina and anti-arrhythmic effect, For patients with ischemic heart disease, tachyarrhythmia in hypertensive patients is particularly applicable, and for catecholamines and plasma renin high young hypertensive and mood swings related hypertensive patients may be preferred. However, the general beta blockers such as propranolol and other applications often cause bradycardia, but also induced heart failure, affecting blood lipids, glucose metabolism and other side effects, to a certain extent, limit its application.